GHRP-6 vs Tesamorelin
Well Studied vs FDA Approved
synergistic Mechanism-based · 55% GHRP-6 and Tesamorelin amplify GH release through complementary mechanisms (GHRH primes, GHRP triggers). This is a well-established synergistic combination — expect significantly greater GH output than either alone.
Molecular Data
GHRP-6 Tesamorelin
Weight 873 Da 5,135.9 Da
Half-life 15-60 minutes 26-38 minutes
Chain 6 amino acids 44 amino acids
Type Synthetic hexapeptide GHRH analog
Key Benefits
GHRP-6
01 Potent stimulation of natural growth hormone release
02 Significant increase in appetite (beneficial for bulking/weight gain)
03 Enhanced muscle growth through elevated GH and IGF-1
04 Improved fat metabolism and body composition
05 Cardioprotective effects observed in research
06 Enhanced recovery from exercise and injury
07 Cytoprotective and anti-inflammatory properties
08 Maintains natural GH pulsatile release
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
GHRP-6
100-300 mcg per injection / 2-3 times daily (morning, post-workout optional, before bed)
GH optimization 100 mcg 2-3x daily
Enhanced results 200-300 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Appetite/bulking 100-200 mcg Before meals
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
GHRP-6
Intense hunger/increased appetite (most notable side effect)
Water retention
Tingling or numbness in extremities
Tiredness or lethargy after injection
Mild headache
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
Diabetes (use with caution)
WADA prohibited for competitive athletes
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
GHRP-6 Tesamorelin
Status Well Studied FDA Approved
References 3 studies 5 studies
Latest — June 2025
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.